Analysis of Maternal Serum PLGF, VEGF, and sFlt-1 in Placenta Accreta Spectrum and Normal Pregnancy
F1000Research · 08.07.2026 · 15 · 213
DOI: 10.12688/f1000research.175924.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, online erschienen am 08.07.2026. Verfasst von Yusrawati Yusrawati und 4 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Placenta Accreta Spectrum (PAS) is a severe obstetric condition characterized by abnormal placental trophoblast invasion into the myometrium, leading to significant maternal morbidity and mortality. While imaging remains the cornerstone of prenatal diagnosis, limitations in sensitivity and availability necessitate the exploration of adjunctive biomarkers. Dysregulation of angiogenic pathways has been implicated in PAS pathogenesis. To evaluate maternal serum levels of angiogenic biomarkers—placental growth factor (PlGF), vascular endothelial growth factor (VEGF), and soluble fms-like tyrosine kinase-1 (sFlt-1)—and to compare their expression between PAS and normal pregnancies.
Methods
This prospective case–control study was conducted at RSUP Dr. M. Djamil Padang between March and November 2025. Eighty-eight pregnant women were enrolled, comprising 44 PAS cases and 44 gestational age–matched controls with normal placentation. Maternal serum samples were collected at 32–34 weeks of gestation and analyzed for PlGF, VEGF, and sFlt-1 using enzyme-linked immunosorbent assay (ELISA). Demographic, obstetric, ultrasound, laboratory, and neonatal data were recorded. Statistical analysis was performed using appropriate parametric and non-parametric tests, with p < 0.05 considered statistically significant.
Results
Maternal demographic characteristics, fetal biometric parameters, neonatal outcomes, and baseline biochemical profiles were comparable between groups. Median maternal serum PlGF and VEGF levels were significantly lower in the PAS group compared with controls (PlGF: 3.825.660 vs 4.086.680 pg/mL, p = 0.032; VEGF: 8.713.645 vs 12.524.675 pg/mL, p = 0.008). Although sFlt-1 levels showed a decreasing trend in PAS cases, the difference was not statistically significant (p = 0.102). Alpha-fetoprotein (AFP) levels did not differ significantly between groups (p = 0.114).
Conclusion
PAS is associated with significant reductions in maternal serum PlGF and VEGF, reflecting angiogenic dysregulation and abnormal placental invasion. These biomarkers may serve as complementary tools to imaging modalities for improving prenatal detection of PAS. Larger studies are warranted to validate their clinical utility and integration into diagnostic algorithms.
Zitieren
APA
Yusrawati, Y., Aladin, A., Antonus, P. A., Iqbal, M., & Hidayani, R. D. (2026). Analysis of Maternal Serum PLGF, VEGF, and sFlt-1 in Placenta Accreta Spectrum and Normal Pregnancy. F1000Research, 15, 213. https://doi.org/10.12688/f1000research.175924.2
Vancouver
Yusrawati Y, Aladin A, Antonus PA, Iqbal M, Hidayani RD. Analysis of Maternal Serum PLGF, VEGF, and sFlt-1 in Placenta Accreta Spectrum and Normal Pregnancy. F1000Research. 2026;15:213. doi:10.12688/f1000research.175924.2
BibTeX
@article{Yusrawati2026,
author = {Yusrawati, Yusrawati and Aladin, Aladin and Antonus, Puja Agung and Iqbal, Muhammad and Hidayani, Rahmalia Destri},
title = {Analysis of Maternal Serum PLGF, VEGF, and sFlt-1 in Placenta Accreta Spectrum and Normal Pregnancy},
journal = {F1000Research},
year = {2026},
volume = {15},
pages = {213},
doi = {10.12688/f1000research.175924.2}
}
EUVIMED